Swiss pharmaceutical major Roche informed Tuesday that experimental schizophrenia drug bitopertin failed in two late-stage trials.
The results found from the drug use could not reduce negative symptoms among patients. The company will continue with third late-stage study.
Bitopertin was used with along with antipsychotics to reduce symptoms of schizophrenia. Bitopertin could have been the first drug in new class of treatment for the ailment. As per official communication from Roche, the phase III trials could not offer significant improvement after 24 week treatment.
The company is working on several projects in neuroscience which include drug development for multiple sclerosis, schizophrenia and Alzheimer’s disease.
The impact on stock could be minimal as market analysts were not having big expectations from bitopertin. The company statement said that the future course will be decided after considering the data from ongoing studies.
Bitopertin is a glycine transporter type 1 (GlyT1) inhibitor. It works by increasing the level of the neurotransmitter glycine by inhibiting its reuptake from the synaptic cleft.
Schizophrenia impacts 26 million people across the world. University of Birmingham research team has also been involved in the research and development of the drug for schizophrenia.
By Naledi Nyamambi
Tuesday 21 January 2014
News Tonight Africa
Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.